Any time a stock moves down 75% over a given period of time, investors have reason to be concerned. When such a move happens in a given trading day, it’s time to ring the alarm bells. For investors in ...

Deciphera Pharmaceuticals (NASDAQ:DCPH) announced on Monday that Japan’s ONO Pharmaceutical has agreed to acquire the cancer drug developer for a total equity value of $2.4B. ONO will acquire all ...

On Monday, Japanese pharma company ONO Pharmaceutical agreed to acquire Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) for $25.60 per share in cash, for a total equity value of $2.4 billion. Deciphera ...

Deciphera Pharmaceuticals (NASDAQ:DCPH) announced Monday that its experimental therapy, vimseltinib, reached the primary endpoint and all key secondary endpoints in a Phase 3 trial for patients with ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Deciphera Pharmaceuticals, Inc. (DCPH) one of those stocks right now? By taking a ...

Deciphera Pharmaceuticals, Inc. DCPH reported third-quarter 2023 loss of 58 cents per share, narrower than the Zacks Consensus Estimate of a loss of 60 cents. In the year-ago quarter, DCPH had ...

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve ...

Sometimes, a big sell off can also be a big opportunity. But that’s not the case here with biotech play Deciphera Pharmaceuticals (NASDAQ:DCPH). On Nov. 5, DCPH stock took a sudden plunge of more than ...

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve ...